Recent studies suggest that moderate AS is not a benign condition and is associated with increased mortality and morbidity especially when LV function is already reduced.
The PROGRESS trial
For health care professionals
Now enrolling
About the study
The objective of the PROGRESS CAP study is to provide patients who have moderate, calcific aortic stenosis continued access to the SAPIEN 3 transcatheter heart valve family, in order to expand device and procedure-related learnings and increase the representation of underserved populations.
Contact our Patient Support Center to find a participating hospital near you
Why study moderate aortic stenosis?
Aortic stenosis is known to be a progressive disease with a highly variable and unpredictable rate of progression. Different degrees of obstruction lead to a spectrum of adaptive and eventually pathological cardiac mechanisms, ranging from left ventricular (LV) hypertrophy, myocardial fibrosis, LV depression, and subsequent consequences extending beyond the aortic valve and LV (i.e., atrial fibrillation, secondary mitral regurgitation, pulmonary artery hypertension, right ventricle dysfunction).
Disease Progression in Aortic Stenosis
Histopathology and cardiac magnetic resonance imaging have shown that progressive pressure overload impacts the LV with fibrosis seen even before AS is severe.
Recent data suggest that the rate of progression from mild-moderate AS to more severe AS is highly variable, unpredictable, and that some subgroups of patients with moderate AS are associated with a worse prognosis.
The objective of the PROGRESS CAP study is to provide patients who have moderate, calcific aortic stenosis continued access to the
SAPIEN 3 transcatheter heart valve family, in order to expand device and procedure-related learnings and increase the representation of underserved populations.
Study design
The Edwards SAPIEN 3, SAPIEN 3 Ultra,
and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valves
SAPIEN 3 valve sizes
SAPIEN 3 Ultra valve sizes
SAPIEN 3 Ultra RESILIA valve sizes
The SAPIEN 3 Ultra system procedural animation
We’re here for you
We are committed to providing the highest levels of customer service to help our patients improve their quality of life. For any questions, or if you are interested in being part of this study, please contact the Edwards Patient Support Center. For details about the study, visit NCT04889872 at Clinical Trials.gov.
Give us a call
888.713.1564
Send us an email
CAUTION: INVESTIGATIONAL DEVICES
CAUTION: INVESTIGATIONAL DEVICES
CAUTION: INVESTIGATIONAL DEVICES. Limited by Federal (USA) law to investigational use only. The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA transcatheter heart valves are investigational devices when used in patients with moderate, calcific aortic stenosis. These devices are not available for marketing or commercial sale in the United States for patients with moderate aortic stenosis.